Navigation Links
Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Date:9/18/2007

KENILWORTH, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) will provide a live audio webcast of a presentation by Alex Kelly, vice president, Investor Relations, speaking about the company at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference in London on Sept. 19, 2007, at approximately 9 a.m. (London) (approximately 4 a.m. EDT).

Kelly will be speaking on the company's financial performance and the planned acquisition of Organon BioSciences N.V. (OBS). He may also reiterate the company's outlook, as previously stated in the company's second quarter 10-Q, on the following:

-- Sales of VYTORIN and ZETIA are expected to grow in 2007. However,

there is growing competition for Schering-Plough's key brands;

-- Gross margin for the full year of 2007 is expected to improve versus

2006, primarily as a result of annual cost savings of approximately

$100 million expected from the company's manufacturing streamlining

actions in 2006 and improved product mix. However, gross margin in the

second half of 2007 is expected to be slightly lower than the first

half due to the seasonality of some respiratory products;

-- As Schering-Plough's pipeline continues to progress, the company

expects that the number of patients in its clinical trials will

continue to increase in the remainder of 2007. R&D expenses, excluding

any upfront payments, are expected to continue to grow faster than

adjusted net sales in 2007. Adjusted net sales is defined as net sales

plus an assumed 50 percent of the global cholesterol joint venture net

sales;

-- The company's full-year 2007 tax rate is expected to be in the mid-

teens on a GAAP basis, but vary between quarters depending on the

product and country mix of earnings; and

-- In advance of the planned acquisition of OBS, the company will incur

integration planning-related costs and potential foreign currency-

related activity associated with the purchase. The transaction is

anticipated to be accretive to the company's earnings per share in the

first full year, excluding purchase-accounting adjustments and

acquisition-related costs. The company expects to achieve annual

synergies of $500 million, however, it is expected that it will take

three years from the closing to reach this level of synergies.

A live audio webcast of the presentation will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available later that day.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. New Sonic Foundry search engine finds words, phrases in video presentations
3. Sonic Foundry creates search engine for 7,000 expert video presentations
4. InvestMidWest calls for business presentations
5. BxVideo designs Web hosting service for Sonic Foundry media presentations
6. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
7. Ethanol plant builder to expand Merrill facility
8. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
9. The state of global biotech: An Ernst & Young perspective
10. Doyle announces new energy, global warming policies
11. Lucigen Corp. enters global licensing agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):